Clinical Trial Update: Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating cabozantinib to overcome carfilzomib resistance in refractory multiple myeloma has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• cabozantinib (cabozantinib)

Snippet

Sponsor: University of Nebraska | Conditions: Multiple Myeloma, Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-12-23